In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genfit SA

www.genfit.com

Latest From Genfit SA

Zydus Cadila Strides Ahead With NASH Filing In India

Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.

 

Policy & Regulation Liver & Hepatic

CymaBay Shelves NASH Drug Seladelpar On Liver Safety Concerns

Atypical histological findings from a Phase IIb NASH study lead CymaBay to terminate mid-stage studies in NASH and PSC and place a Phase III PBC trial on hold.

Clinical Trials Drug Safety

Galectin’s NASH Phase III Trial Will Use Surrogate Measures Of Esophageal Varices

Other NASH registration trails have targeted fibrosis, but Galectin's mostly-resolved discussions with US FDA will allow the belapectin program to focus of signs and symptoms of the disease.

Liver & Hepatic Drug Approval Standards

Galectin’s NASH Challenges: Paying For Phase III, Carving Market Niche

Galectin faces a dual challenge - do its planned trial well and trust that the study design will lead the galectin-3 inhibitor belapectin to a niche position in NASH.

Clinical Trials Drug Approval Standards
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Hepatic (Liver)
  • Immune Disorders
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Genfit SA
  • Senior Management
  • Jean-Francois Mouney, Chmn. & CEO
    Nathalie Huitorel, EVP, CFO & Chief Administrative Officer
    Dean Hum, PhD, COO
    Carol L Addy, MD, CMO
  • Contact Info
  • Genfit SA
    Phone: (33) 3 20 16 40 00
    885 Ave. Eugene Avinee
    Parc Eurasante
    Loos, 59120
    France
UsernamePublicRestriction

Register